- Home
- XPRO vs ELVN Comparison
XPRO vs ELVN Comparison
Compare XPRO & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XPRO | ELVN |
|---|---|---|
| Founded | 1938 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XPRO | ELVN |
|---|---|---|
| Price | $18.13 | $43.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $16.00 | ★ $43.40 |
| AVG Volume (30 Days) | 996.8K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $522,493,000.00 | N/A |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | $39.61 | ★ N/A |
| Revenue Growth | ★ 14.89 | N/A |
| 52 Week Low | $7.57 | $14.79 |
| 52 Week High | $18.73 | $48.53 |
Technical Indicators
Market Signals| Indicator | XPRO | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 55.80 |
| Support Level | $15.39 | $16.84 |
| Resistance Level | $18.60 | $48.53 |
| Average True Range (ATR) | 0.57 | 2.29 |
| MACD | 0.17 | -0.65 |
| Stochastic Oscillator | 97.33 | 7.84 |
Price Performance
Historical ComparisonAbout XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.